Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer

Gallucci, Michele; Vico, Erika; Merola, Roberta; Leonardo, Costantino; Sperduti, Isabella; Felici, Alessandra; Sentinelli, Steno; Cantiani, R.; Orlandi, Giulia; Cianciulli, A. M.

doi:10.1016/j.yexmp.2007.08.017

Cited by 8 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The INK4a gene on locus 9p21 codes for the proteins p16 and p19ARF and is one of the most frequently affected loci in bladder cancer [46,47] . Homozygous deletions of the gene, detected by fluorescence in situ hybridization, have been associated with adverse outcome.…”

Section: P16/ink4amentioning

confidence: 99%

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Rosenblatt¹,

Jonmarker²,

Lewensohn³

et al. 2008

Tumor Biol

View full text Add to dashboard Cite

The management and prognostication of patients with urothelial carcinomas (UCs), the most common histological type of bladder cancer, is mainly based on clinicopathological parameters. Several markers have been proposed to monitor this disease, including individual cell cycle-related proteins such as p53, pRb, p16, p21 and p27. Other putative markers are the oncogene products of FGFR3 and the ErbB family, proliferation markers including Ki-67, Aurora-A and survivin and different components within the immune system. In this review, a total of 12 parameters were evaluated and their discriminatory power compared. It is concluded that, in single-marker analyses, the proliferation markers Ki-67, survivin and Aurora-A offer the best potential to predict disease progression since they were all able to demonstrate independent prognostic power in repeated studies. Markers related to the immune system (e.g. CD8+ cells, regulatory T cells and cyclooxygenase-2 expression) or oncogene products of the ErbB family and FGFR3 are less powerful predictors of outcome or have not been equally well studied. The cell cycle-related proteins p53, pRb, p16, p21 and p27 have been extensively studied, but their usefulness as single prognostic markers remains unclear. However, in multimarker analyses, these markers appear to add prognostic information, indicating that they may contribute to more accurate treatment of UC.

show abstract

Section: P16/ink4amentioning

confidence: 99%

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Rosenblatt¹,

Jonmarker²,

Lewensohn³

et al. 2008

Tumor Biol

View full text Add to dashboard Cite

show abstract

“…Due to any of these events its expression at the level of protein p16 INK4a may become partly or fully lost. For example, homozygous INK4a deletions depriving cell of p16 INK4a synthesis were found in ~ 30-50 % of BC specimens (Aveyard, Knowles, 2004;Gallucci et al, 2007). Thus our data might prove unsuitability of p16 INK4a for role of the HPV-associated BC marker.…”

Section: Study Of Ink4a Expression In Dna Hpv16-positive Bladder Cancmentioning

confidence: 75%

“…The point is, according to literature data, that factors determining INK4a expression in HPV-associated BC may differ in essence from those in HPV-positive CC. Thus in BC, in contrast to CC, INK4a undergoes frequent deletions, point mutations or promoter methylations (Ruas, Peters, 1998;Aveyard, Knowles, 2004;Gallucci et al, 2007). Due to any of these events its expression at the level of protein p16 INK4a may become partly or fully lost.…”

Section: Study Of Ink4a Expression In Dna Hpv16-positive Bladder Cancmentioning

confidence: 99%

Role of HPV in Urothelial Carcinogenesis: Current State of the Problem

Волгарева¹,

Матвеев²,

Головина³

2012

Bladder Cancer - From Basic Science to Robotic Surgery

View full text Add to dashboard Cite

“…In contrast to cervical cancer, INK4a gene in bladder cancer is often subjected to deletions and point mutations and methylated in the promotor region [3,4,11]. Any of these events can completely or partially suppress INK4a expression at the protein level.…”

mentioning

confidence: 99%

“…Any of these events can completely or partially suppress INK4a expression at the protein level. Homozygotic deletions of INK4a, as a result of which the cell is no longer able of producing p16 INK4a , were detected in ~30-50% specimens of bladder cancer [3,4]. It was never studied whether hyperexpression of p16 INK4a is characteristic of HPV-positive urothelium…”

mentioning

confidence: 99%

Cellular Expression of INK4a Gene in Cells of Bladder Cancer Associated with Human Papilloma Virus-16

et al. 2010

View full text Add to dashboard Cite

Hyperexpression of p16(INK4a) protein is an early marker of cervical cancer. Hyperexpression of INK4a gene encoding this protein at the level of mRNA and p16(INK4a) was detected in tumor cells of some patients with bladder cancer associated with human papilloma virus-16. However, in contrast to cervical cancer, this phenomenon in urothelial carcinomas does not correlate with expression of human papilloma virus-16 oncogenes E6 and E7.

show abstract

Adverse genetic prognostic profiles define a poor outcome for cystectomy in bladder cancer

Cited by 8 publications

References 22 publications

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder Cancer

Role of HPV in Urothelial Carcinogenesis: Current State of the Problem

Cellular Expression of INK4a Gene in Cells of Bladder Cancer Associated with Human Papilloma Virus-16

Contact Info

Product

Resources

About